ExPEC4V
Pharmaceutical compound
From Wikipedia, the free encyclopedia
ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection.[2][1][3][4] It is an Escherichia coli polysaccharide conjugate vaccine.[2][1][4] The vaccine is administered by intramuscular injection.[1] It is being developed by GlycoVaxyn and Johnson & Johnson.[2] As of November 2023, ExPEC4V is in phase 2 clinical trials.[2] There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054).[4][5] In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.[6]
TargetEscherichia coli[1]
Vaccine typeconjugate[1]
Other namesExPEC4-V; ExPEC-4V; ExPECV4; ExPEC-V4; JNJ-63871860; JNJ63871860
| Vaccine description | |
|---|---|
| Target | Escherichia coli[1] |
| Vaccine type | conjugate[1] |
| Clinical data | |
| Other names | ExPEC4-V; ExPEC-4V; ExPECV4; ExPEC-V4; JNJ-63871860; JNJ63871860 |
| Routes of administration | Intramuscular injection[1] |
